Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 246.59 Billion KRW | 124.45% |
| 2022 | 109.9 Billion KRW | 15.99% |
| 2021 | 94.75 Billion KRW | -23.54% |
| 2020 | 123.93 Billion KRW | 66.19% |
| 2019 | 74.57 Billion KRW | -1.54% |
| 2018 | 75.73 Billion KRW | -2.6% |
| 2017 | 77.76 Billion KRW | 26.96% |
| 2016 | 61.24 Billion KRW | 43.42% |
| 2015 | 42.7 Billion KRW | -20.81% |
| 2014 | 53.93 Billion KRW | 615.35% |
| 2013 | 7.53 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 35.86 Billion KRW | 52.04% |
| 2024 Q1 | 26.75 Billion KRW | -76.61% |
| 2023 Q3 | 55.73 Billion KRW | 23.85% |
| 2023 Q4 | 114.39 Billion KRW | 105.25% |
| 2023 FY | 246.68 Billion KRW | 124.45% |
| 2023 Q1 | 31.49 Billion KRW | 69.38% |
| 2023 Q2 | 44.99 Billion KRW | 42.89% |
| 2022 Q3 | 39.32 Billion KRW | 45.96% |
| 2022 Q2 | 26.93 Billion KRW | 7.54% |
| 2022 Q1 | 25.05 Billion KRW | 394.12% |
| 2022 FY | 109.9 Billion KRW | 15.99% |
| 2022 Q4 | 18.59 Billion KRW | -52.72% |
| 2021 Q1 | 21.87 Billion KRW | 63.81% |
| 2021 Q2 | 31.64 Billion KRW | 44.65% |
| 2021 Q3 | 36.17 Billion KRW | 14.31% |
| 2021 Q4 | 5.06 Billion KRW | -85.98% |
| 2021 FY | 94.75 Billion KRW | -23.54% |
| 2020 Q1 | 25.85 Billion KRW | 23.97% |
| 2020 Q3 | 48.35 Billion KRW | 32.95% |
| 2020 Q4 | 13.35 Billion KRW | -72.38% |
| 2020 Q2 | 36.37 Billion KRW | 40.65% |
| 2020 FY | 123.93 Billion KRW | 66.19% |
| 2019 Q2 | 18.23 Billion KRW | 14.65% |
| 2019 FY | 74.57 Billion KRW | -1.54% |
| 2019 Q4 | 20.85 Billion KRW | 6.55% |
| 2019 Q3 | 19.57 Billion KRW | 7.34% |
| 2019 Q1 | 15.9 Billion KRW | -13.69% |
| 2018 Q3 | 20.43 Billion KRW | 13.01% |
| 2018 Q4 | 18.42 Billion KRW | -9.8% |
| 2018 FY | 75.73 Billion KRW | -2.6% |
| 2018 Q2 | 18.07 Billion KRW | -3.84% |
| 2018 Q1 | 18.8 Billion KRW | -10.23% |
| 2017 Q1 | 16.76 Billion KRW | 0.0% |
| 2017 FY | 77.76 Billion KRW | 26.96% |
| 2017 Q2 | 16.33 Billion KRW | -2.56% |
| 2017 Q3 | 23.72 Billion KRW | 45.26% |
| 2017 Q4 | 20.94 Billion KRW | -11.73% |
| 2016 Q1 | 8.25 Billion KRW | -21.76% |
| 2016 Q2 | 10.57 Billion KRW | 28.08% |
| 2016 Q3 | 22.24 Billion KRW | 110.35% |
| 2016 Q4 | - KRW | -100.0% |
| 2016 FY | 61.24 Billion KRW | 43.42% |
| 2015 FY | 42.7 Billion KRW | -20.81% |
| 2015 Q4 | 10.55 Billion KRW | -10.48% |
| 2015 Q3 | 11.78 Billion KRW | 45.38% |
| 2015 Q2 | 8.1 Billion KRW | -33.86% |
| 2015 Q1 | 12.25 Billion KRW | 48.22% |
| 2014 Q1 | 15.23 Billion KRW | 0.0% |
| 2014 FY | 53.93 Billion KRW | 615.35% |
| 2014 Q2 | 17.4 Billion KRW | 14.22% |
| 2014 Q3 | 13.01 Billion KRW | -25.22% |
| 2014 Q4 | 8.27 Billion KRW | -36.46% |
| 2013 FY | 7.53 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -67547.236% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | -220.751% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 409.947% |
| HANDOK Inc. | 12.57 Billion KRW | -1860.431% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 12497.263% |
| Yuhan Corporation | 74.56 Billion KRW | -230.728% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -2106.021% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 1466.767% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | -9.656% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -7969.191% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -1618.411% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -41247.774% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -25487.067% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -812.268% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -67547.236% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 3279.443% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -6013.582% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 452.535% |
| JW Holdings Corporation | 143.66 Billion KRW | -71.648% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 561.644% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -145.852% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 620.335% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -3460.009% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -3710.821% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -2724.288% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -67547.236% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -405.662% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | -84.848% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -145.852% |
| Yuhan Corporation | 74.56 Billion KRW | -230.728% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -1078.762% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -7810.429% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -473.554% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -145.852% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -1103.842% |
| Korea United Pharm Inc. | 54.94 Billion KRW | -348.773% |
| CKD Bio Corp. | -20.15 Billion KRW | 1323.665% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -665.057% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -874.621% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -658.181% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 620.335% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -643.96% |
| Boryung Corporation | 68.26 Billion KRW | -261.228% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 757.655% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -1618.411% |
| JW Lifescience Corporation | 32.09 Billion KRW | -668.426% |